Business Wire

“Dense Air” The Neutral Host Small Cell Operator

Share

Today we introduce “Dense Air”, a new wholesale network operator, that “enhances and extends” the coverage and capacity of existing Mobile Networks as a “Carrier of Carriers” operator, typically on a neutral host basis. The announcement coincides with the 2018 Mobile World Congress in Barcelona, Spain, where Dense Air is exhibiting (26 February–1 March 2018).

Dense Air uses Airspan’s comprehensive portfolio set of 4G and 5G small cells to offer services to Mobile Operators in licensed spectrum dedicated to small cells for densification/extension deployments.

“We are very excited about the opportunity to deliver a completely new type of service to mobile carriers. Dense Air’s wholesale service offering will complement the investments carriers have made in their Macro RAN,” said Paul Senior, Acting CEO of Dense Air. “By adding small cells, running in dedicated licensed spectrum to Macro networks at cell edge either outdoors or indoors, we can dramatically improve the service experience to end users, increase speeds and network capacity. Importantly, Dense Air does not and will not offer retail mobile services and does not compete in any way with mobile service providers.”

“The economics of both 4G and 5G small cell deployments can be dramatically improved when deployed using a neutral host solution, i.e. when a single network of small cells can host multiple operators. Our mission is to help MNOs and MVNOs improve their networks by densification without the need to spend CAPEX”.

Dense Air is an optimised network densification and network extension service.

  • Solution delivered using Indoor and Outdoor Small Cells
  • Service operates in licensed, dedicated spectrum
  • Dense Air small cells provide services on a “Neutral Host” basis
  • We support 4G LTE and LTE Pro networks and later 5G NR
  • Dense Air fills coverage holes and capacity weak spots in Macro Networks
  • Services are offered on a wholesale “Carrier of Carriers” basis to Mobile Network Operators
  • We DO NOT compete with Mobile Operators or other Service Providers
  • Our services are delivered in Urban, Suburban or Rural areas
  • The focus is on mobile use cases, including eMBB, IoT, Public Safety
  • We also enable Private LTE Networks for Large Enterprises and Governments

Airspan’s product and technologies for 4G LTE and 5G are naturally suited to small cell centric network architectures. Airspan's unique innovation and technology leadership in intelligent small cells with integrated LTE relay and millimeter-wave backhaul technologies will allow Dense Air to massively densify traditional mobile networks.

About DENSE AIR:

Dense Air is based in London, UK and has offices in Ireland and Belgium, it’s target launch markets. Dense Air uses unique “carrier of carriers” neutral host small cell technologies to deliver cost effective densification to any existing LTE Mobile Carrier or Service Provider. Dense Air is conducting extensive trials and Proof-of-Concepts in 2018 and will offer commercial services in 2019.

www.denseair.net

media@denseair.net

About Airspan Networks Inc.:

Airspan (OTC PINK : AIRO) is a leading 4G and 5G RAN solution provider, with over 1000 customers in over 100 countries. Airspan is regularly recognized as a leader and pioneer in LTE Access and innovative Backhaul solutions. Airspan has an expansive product portfolio, which includes indoor and outdoor small cells, and all-outdoor, compact Micro and Macro base stations, a variety of user devices and network optimization products. These connectivity solutions operate in bands from 400 MHz up to 6.4 GHz and 60-80GHz millimeter wave. www.airspan.com.

Airspan is not subject to the informational reporting requirements of the Securities Exchange Act of 1934 and, accordingly, does not file reports, financial statements, proxy statements, information statements or other information with the Securities and Exchange Commission. This press release may contain forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. We do not assume any obligation to update any forward-looking statements.

Airspan Networks Inc.

mediarelations@airspan.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dense Air
Paul Senior
Tel: 01895 467100
media@denseair.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release

IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye